Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Rhea-AI Summary

Sionna Therapeutics (Nasdaq: SION) announced management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 2:00 p.m. ET. A live webcast and a replay will be available on Sionna's Investors "Events" page.

The presentation focuses on the company’s clinical-stage programs targeting normalization of CFTR function for cystic fibrosis.

News Market Reaction – SION

-7.12%

23 alerts

-7.12% News Effect

-15.7% Trough in 5 hr 48 min

-$132M Valuation Impact

$1.73B Market Cap

1.2x Rel. Volume

On the day this news was published, SION declined 7.12%, reflecting a notable negative market reaction. Argus tracked a trough of -15.7% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $132M from the company's valuation, bringing the market cap to $1.73B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Summit presentation time: 2:00 p.m. ET

1 metrics

Summit presentation time 2:00 p.m. ET Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026

Market Reality Check

Price: $36.16 Vol: Volume 312,281 is roughly...

normal vol

$36.16 Last Close

Volume Volume 312,281 is roughly in line with the 20-day average of 305,768 (relative volume 1.02). normal

Technical Shares at $44.48 are 1.16% below the 52-week high of $45.00 and trading above the 200-day MA at $27.06.

Peers on Argus

Peer moves are mixed: MAZE (+2.46%) and SYRE (+1.59%) are up, while LENZ (-5.07%...

Peer moves are mixed: MAZE (+2.46%) and SYRE (+1.59%) are up, while LENZ (-5.07%) and ORIC (-1.48%) are down, suggesting stock-specific rather than broad sector momentum.

Common Catalyst Both SION and MAZE announced participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, pointing to a shared conference-related news theme among select peers.

Historical Context

5 past events · Latest: Jan 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Conference presentation	Neutral	+4.2%	Announced J.P. Morgan Healthcare Conference presentation and webcast access details.
Nov 24	Investor conferences	Neutral	+1.6%	Planned participation in two December 2025 healthcare investor conferences.
Nov 05	Earnings and pipeline	Positive	-1.6%	Reported Q3 2025 results, strong cash of $325M, and multiple CF trial initiations.
Nov 04	Investor conferences	Neutral	-1.2%	Announced November 2025 investor conference fireside chats and webcast logistics.
Oct 24	Clinical data update	Positive	-1.0%	Presented Phase 1 and preclinical data for SION‑719 and SION‑451 in CF.

Pattern Detected

Recent history shows frequent conference and data updates with generally modest, often mixed, price reactions, while a fundamentally positive earnings/pipeline update saw a small negative move.

Recent Company History

Over the last few months, Sionna has regularly communicated via conferences and clinical updates. On Oct 24, 2025, it presented Phase 1 and preclinical data for CF programs, followed by multiple investor conference announcements in November 2025 and a J.P. Morgan Healthcare Conference appearance on Jan 13, 2026. The Q3 2025 earnings on Nov 5, 2025 highlighted Phase 2a initiation for SION‑719, a Phase 1 dual‑combination trial for SION‑451, and cash of $325.0M funding operations into 2028. Today’s Guggenheim summit presentation fits this ongoing investor-relations cadence.

Market Pulse Summary

The stock moved -7.1% in the session following this news. A negative reaction despite this conferenc...

Analysis

The stock moved -7.1% in the session following this news. A negative reaction despite this conference-focused update would fit a pattern where even constructive or neutral news, such as the positive Q3 2025 pipeline and cash update of $325.0M, has sometimes seen muted or negative follow-through. The current release mainly adds another investor-relations touchpoint without new trial readouts or financial changes. In that context, any sizable decline could reflect profit-taking near the $45.00 52-week high or sensitivity around prior insider sales rather than a shift in fundamentals.

Key Terms

cystic fibrosis, cftr, cystic fibrosis transmembrane conductance regulator

3 terms

cystic fibrosis medical

"revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing"

A genetic disease that causes the body to produce thick, sticky mucus that clogs airways and digestive passages, leading to ongoing lung infections, breathing difficulty, and problems absorbing nutrients. For investors, cystic fibrosis matters because treatments range from symptom management to pricey, targeted drugs that can change patient outcomes; progress in therapies, clinical trial results, regulatory approvals, and reimbursement decisions can significantly affect the commercial value of companies working in this area.

cftr medical

"normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein"

CFTR is a gene that makes a protein acting like a tiny gate in cell membranes to control the flow of salt and water; when the gate works properly it helps keep mucus thin and organs functioning. Investors care because mutations in CFTR drive serious diseases and create demand for diagnostics, drugs and long-term treatment revenue; progress or setbacks in therapies, approvals or patents directly affect company value.

cystic fibrosis transmembrane conductance regulator medical

"novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein"

A cystic fibrosis transmembrane conductance regulator (CFTR) is a protein that acts like a microscopic gate or faucet on cell surfaces, controlling the movement of salt and water into and out of cells. It matters to investors because mutations in CFTR cause cystic fibrosis and drive development of targeted drugs, tests, and therapies; breakthroughs or regulatory decisions around CFTR-targeting products can significantly affect the value and prospects of companies in biopharma and diagnostics.

AI-generated analysis. Not financial advice.

WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11^th, 2026 at 2:00 p.m. ET.

A live webcast of the presentation will be available under the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. A replay will also be available following the event.

About Sionna Therapeutics 
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which occurs in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.

Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Media Contact 
Adam Daley 
CG Life 
212.253.8881 
adaley@cglife.com 

Investor Contact 
Juliet Labadorf 
ir@sionnatx.com 

FAQ

When will Sionna Therapeutics (SION) present at the Guggenheim Biotech Summit 2026?

Sionna will present on Wednesday, February 11, 2026 at 2:00 p.m. ET. According to the company, management will deliver the presentation live at that scheduled time during the Guggenheim Emerging Outlook: Biotech Summit 2026.

How can investors watch Sionna Therapeutics (SION) presentation on February 11, 2026?

Investors can watch via a live webcast on Sionna’s Investors "Events" page. According to the company, the webcast will stream live and a replay will be posted after the event for on-demand viewing.

What topics will Sionna Therapeutics (SION) cover at the Guggenheim Biotech Summit?

The presentation will cover Sionna’s clinical-stage programs targeting CFTR normalization for cystic fibrosis. According to the company, management will discuss their approach to developing medicines that aim to normalize CFTR protein function.

Will a replay of Sionna Therapeutics (SION) Guggenheim presentation be available after February 11, 2026?

Yes, a replay will be made available on the company’s Investors "Events" page after the live event. According to the company, the replay will remain accessible following the presentation for investors and other viewers.